Compare AYTU & RCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AYTU | RCG |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 20.6M |
| IPO Year | 2015 | 1996 |
| Metric | AYTU | RCG |
|---|---|---|
| Price | $2.17 | $2.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.33 | N/A |
| AVG Volume (30 Days) | ★ 23.3K | 4.1K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,632,080.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 277.47 | N/A |
| 52 Week Low | $1.65 | $2.40 |
| 52 Week High | $3.07 | $3.31 |
| Indicator | AYTU | RCG |
|---|---|---|
| Relative Strength Index (RSI) | 37.67 | 53.99 |
| Support Level | $2.07 | $2.89 |
| Resistance Level | $2.32 | $3.00 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 8.33 | 100.00 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
RENN Fund Inc is a registered, non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with above-market rates of return through capital appreciation and income by a long-term, value oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities, including convertible and non-convertible debt securities or loans, distressed debt, warrants, preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. To a lesser extent, the fund sells short stocks, exchange-traded funds, and exchange-traded notes. It invests in various industries, including communication services, surgical and medical instruments, oil and gas, etc.